Systematic Review of Patients’ and Parents’ Preferences for ADHD Treatment Options and Processes of Care

Patient

Volumn 8, Issue 6, 2015, Pages 483-497

  Schatz, Nicole K ^a   Fabiano, Gregory A ^a   Cunningham, Charles E ^b   dosReis, Susan ^c   Waschbusch, Daniel A ^d   Jerome, Stephanie ^a   Lupas, Kellina ^a   Morris, Karen L ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF MARYLAND   (United States)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; METHYLPHENIDATE;

ASSESSMENT OF HUMANS; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; BEST WORST SCALING; DISCRETE CHOICE EXPERIMENT; DRUG CHOICE; FAMILY CENTERED CARE; FAMILY DECISION MAKING; HEALTH CARE COST; HUMAN; MEDLINE; PARENT PREFERENCE; PARENTAL ATTITUDE; PATIENT CARE; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; PSYCINFO; REVIEW; RISK BENEFIT ANALYSIS; STANDARD GAMBLE INTERVIEW; SUPPORT GROUP; SYSTEMATIC REVIEW; TIME TRADE OFF; TREATMENT OPTION; TREATMENT OUTCOME; TREATMENT PLANNING; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DECISION MAKING; DECISION SUPPORT SYSTEM; FEMALE; MALE; PARENT; PATIENT PARTICIPATION; PSYCHOLOGY;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHOICE BEHAVIOR; DECISION MAKING; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MALE; PARENTS; PATIENT PARTICIPATION; PATIENT PREFERENCE;

EID: 84948576702     PISSN: 11781653     EISSN: 11781661     Source Type: Journal    
DOI: 10.1007/s40271-015-0112-5     Document Type: Review

References (66)

1. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(Suppl 12):10–5.
2. Biederman J, Petty CR, Evans M, Small J, Faraone SV. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res. 2010;177(3):299–304.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Arlington: American Psychiatric Publishing Inc.; 2013.
4. Daley D, Van der Oord S, Ferrin M, Danckaerts M, Doepfner M, Cortese S, et al. Behavioral interventions in attention-deficit/hyperactivity disorder: A meta-analysis of randomized controlled trials across multiple outcome domains. J Am Acad Child Adolesc Psychiatry. 2014;53(8):835.e5–847.e5.
5. Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–22.
6. Conners CK. Forty years of methylphenidate treatment in attention-deficit/hyperactivity disorder. J Atten Disord. 2002;6(Supp1):S30.
7. Evans SW, Owens JS, Bunford N. Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder. J Clin Child Adolesc Psychol. 2014;43(4):527–51.
8. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(5):456–63.
9. Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 2009;29(1):44–50.
10. Marchant BK, Reimherr FW, Halls C, Williams ED, Strong RE, Kondo D, et al. Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine. ADHD Attent Deficit Hyperact Disord. 2011;3(3):237–44.
11. Tanaka Y, Rohde LA, Jin L, Feldman PD, Upadhyaya HP. A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions. J Child Adolesc Psychopharmacol. 2013;23(4):262–70.
12. Safren SA, Otto MW, Sprich S, Winett CL, Wilens TE, Biederman J. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Therapy. 2005;43(7):831–42.
13. Zylowska L, Ackerman DL, Yang MH, Futrell JL, Horton NL, Hale TS, et al. Mindfulness meditation training in adults and adolescents with ADHD: a feasibility study. J Atten Disord. 2008;11(6):737–46.
14. Marcus SC, Wan GJ, Kemner JE, Olfson M. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2005;159(6):572–8.
15. Chronis AM, Chacko A, Fabiano GA, Wymbs BT, Pelham WE Jr. Enhancements to the behavioral parent training paradigm for families of children with ADHD: review and future directions. Clin Child Fam Psychol Rev. 2004;7(1):1–27.
16. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921. doi:10.1097/chi.0b013e318054e724.
17. Vallerand IA, Kalenchuk AL, McLennan JD. Behavioural treatment recommendations in clinical practice guidelines for attention-deficit/hyperactivity disorder: a scoping review. Child Adolesc Ment Health. 2014;19(4):251–8.
18. Kendall T, Taylor E, Perez A, Taylor C. Guidelines: diagnosis and management of attention-deficit/hyperactivity disorder in children, young people, and adults: summary of NICE guidance. BMJ. 2008;337(7672):751–3.
19. Eichner JM, Johnson BH. Patient- and family-centered care and the pediatrician’s role. Pediatrics. 2012;129(2):394–404. doi:10.1542/peds.2011-3084.
20. Bussing R, Zima BT, Gary FA, Garvan CW. Barriers to detection, help-seeking, and service use for children with ADHD symptoms. J Behav Health Serv Res. 2003;30(2):176–89.
21. DosReis S, Mychailyszyn MP, Evans-Lacko SE, Beltran A, Riley AW, Myers MA. The meaning of attention-deficit/hyperactivity disorder medication and parents’ initiation and continuity of treatment for their child. J Child Adolesc Psychopharmacol. 2009;19(4):377–83.
22. Bussing R, Koro-Ljungberg M, Noguchi K, Mason D, Mayerson G, Garvan CW. Willingness to use ADHD treatments: a mixed methods study of perceptions by adolescents, parents, health professionals and teachers. Soc Sci Med. 2012;74(1):92–100.
23. Charach A, Volpe T, Boydell KM, Gearing RE. A theoretical approach to medication adherence for children and youth with psychiatric disorders. Harv Rev Psychiatry. 2008;16(2):126–35.
24. Coletti DJ, Pappadopulos E, Katsiotas NJ, Berest A, Jensen PS, Kafantaris V. Parent perspectives on the decision to initiate medication treatment of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2012;22(3):226–37.
25. Davis CC, Claudius M, Palinkas LA, Wong JB, Leslie LK. Putting families in the center: family perspectives on decision making and ADHD and implications for ADHD care. J Atten Disord. 2012;16(8):675–84. doi:10.1177/1087054711413077.
26. Fiks AG, Mayne S, DeBartolo E, Power TJ, Guevara JP. Parental preferences and goals regarding ADHD treatment. Pediatrics. 2013;132(4):692–702. doi:10.1542/peds.2013-0152.
27. Fiks AG, Mayne S, Hughes CC, DeBartolo E, Behrens C, Guevara JP, et al. Development of an instrument to measure parents’ preferences and goals for the treatment of attention deficit-hyperactivity disorder. Acad Pediatr. 2012;12(5):445–55.
28. Ryan M, Scott D, Reeves C, Bate A, van Teijlingen E. Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess. 2001;5(5):186. doi:10.3310/hta5050.
29. Bleichrodt H, Johannesson M. Standard gamble, time trade-off and rating scale: experimental results on the ranking properties of QALYs. J Health Econ. 1997;16(2):155–75.
30. Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health-a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health (Wiley-Blackwell). 2011;14(4):403–13.
31. Flynn TN, Louviere JJ. Using best-worst scaling choice experiments to measure public perceptions and preferences for healthcare reform in Australia. Patient. 2010;3(4):275–83.
32. Johnson FR, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16(1):3–13.
33. Flynn TN. Valuing citizen and patient preferences in health: recent developments in three types of best-worst scaling. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):259–67. doi:10.1586/erp.10.29.
34. Van Brunt K, Matza LS, Classi PM, Johnston JA. Preferences related to attention-deficit/hyperactivity disorder and its treatment. Patient Prefer Adher. 2011;5:33.
35. Cooper H, Hedges LV. Research synthesis as a scientific enterprise. In: Cooper H, Hedges LV, editors. The handbook of research synthesis. New York: Russell Sage Foundation; 1994. p. 3–28.
36. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.
37. Wymbs F, Cunningham C, Chen Y, Rimas H, Deal K, Waschbusch DA, et al. Examining parents’ preferences for group versus individual parent training programs versus a minimal information alternative for children with ADHD symptoms using a discrete choice conjoint experiment. J Clin Child Adolesc Psychol (in press).
38. Ross M, Bridges JFP, Ng X, Wagner L, Frosch E, Reeves G, dosReis S. A best-worst scaling experiment to prioritize caregiver concerns about attention-deficit/hyperactivity disorder (ADHD) medication for children. Psychiatr Serv. 2014. doi:10.1176/appi.ps.201300525.
39. Lloyd A, Hodgkins P, Dewilde S, Sasané R, Falconer S, Sonuga Barke E. Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: heterogeneity in parent preferences. Int J Technol Assess Health Care. 2011;27(03):215–23.
40. Secnik K, Matza LS, Cottrell S, Edgell E, Tilden D, Mannix S. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom. Med Decis Mak. 2005;25(1):56–70.
41. Fegert JM, Slawik L, Wermelskirchen D, Nübling M, Mühlbacher A. Assessment of parents’ preferences for the treatment of school-age children with ADHD: a discrete choice experiment. Expert Rev Pharmacoecon Outcomes Res. 2011;11(3):245–52.
42. Muhlbacher AC, Nübling M. Analysis of patients’ preferences: direct assessment and discrete-choice experiment in therapy of adults with attention-deficit hyperactivity disorder. Patient. 2010;3(4):285–94.
43. Nafees B, Setyawan J, Lloyd A, Ali S, Hearn S, Sasane R, et al. Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countries. Eur Child Adolesc Psychiatry. 2014;23(12):1189–2000.
44. dosReis S, Ng X, Frosch E, Reeves G, Cunningham C, Bridges JF. Using best-worst scaling to measure caregiver preferences for managing their child’s ADHD––a pilot study. Patient. 2014. doi:10.1007/s40271-014-0098-4TI.
45. Wymbs FA. Examining parents’ preferences for children’s mental health services using conjoint analysis. Rep Emot Behav Disord Youth. 2011;11(3):74–8.
46. Waschbusch DA, Cunningham CE, Pelham WE, Rimas HL, Greiner AR, Gnagy EM, et al. A discrete choice conjoint experiment to evaluate parent preferences for treatment of young, medication naive children with ADHD. J Clin Child Adolesc Psychol. 2011;40(4):546–61. doi:10.1080/15374416.2011.581617.
47. Glenngård AH, Hjelmgren J, Thomsen PH, Tvedten T. Patient preferences and willingness-to-pay for ADHD treatment with stimulants using discrete choice experiment (DCE) in Sweden, Denmark and Norway. Nordic J Psychiatry. 2013;67(5):351–9.
48. Matza LS, Secnik K, Rentz AM, Mannix S, Sallee FR, Gilbert D, et al. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report. Qual Life Res. 2005;14(3):735–47. doi:10.2307/4038822.
49. Mühlbacher AC, Rudolph I, Lincke HJ, Nübling M. Preferences for treatment of attention-deficit/hyperactivity disorder (ADHD): a discrete choice experiment. BMC Health Serv Res. 2009;9:149.
50. Sawtooth Software I. ACBC technical paper (Sawtooth Software technical paper series). 2009.
51. Shah AK, Oppenheimer DM. Heuristics made easy: An effort-reduction framework. Psychol Bull. 2008;134(2):207–22. doi:10.1037/0033-2909.134.2.207.
52. Cunningham CE, Deal K, Chen Y. Adaptive choice-based conjoint analysis: a new patient-centered approach to the assessment of health service preferences. Patient. 2010;3(4):257–73.
53. Orme BK. Getting started with conjoint analysis: strategies for product design and pricing research. Chicago (IL): Research Publishers, LLC.; 2006.
54. Cunningham C, Deal K, Rimas H, Buchanan D, Gold M, Sdao-Jarvie K, et al. Modeling the information preferences of parents of children with mental health problems: a discrete choice conjoint experiment. J Abnorm Child Psychol. 2008;36(7):1123–38. doi:10.1007/s10802-008-9238-4.
55. Deal K. Segmenting patients and physicians using preferences from discrete choice experiments. Patient. 2014;7(1):5–21.
56. Cunningham C, Chen Y, Deal K, Rimas H, McGrath P, Reid G, et al. The interim service preferences of parents waiting for children’s mental health treatment: a discrete choice conjoint experiment. J Abnorm Child Psychol. 2013;41(6):865–77. doi:10.1007/s10802-013-9728-x.
57. Molina BSG, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):484–500. doi:10.1097/CHI.0b013e31819c23d0.
58. Montoya A, Colom F, Ferrin M. Is psychoeducation for parents and teachers of children and adolescents with ADHD efficacious? A systematic literature review. Eur Psychiatry. 2011;26(3):166–75. doi:10.1016/j.eurpsy.2010.10.005.
59. Rollnick S, Miller WR. What is motivational interviewing? Behav Cogn Psychother. 1995;23(4):325–34.
60. De Groot I, Otten W, Dijs-Elsinga J, Smeets H, Kievit J, Marang-Van De Mheen P. Choosing between hospitals: the influence of the experiences of other patients. Med Decis Mak. 2012;32(6):764–78.
61. Godin G, Kok G. The theory of planned behavior: a review of its applications to health-related behaviors. Am J Health Promot. 1996;11(2):87–98.
62. Macinko J, Starfield B, Shi L. The contribution of primary care systems to health outcomes within Organization for Economic Cooperation and Development (OECD) countries, 1970–1998. Health Serv Res. 2003;38(3):831–65.
63. Ungar WJ. Challenges in health state valuation in paediatric economic evaluation. Pharmacoeconomics. 2011;29(8):641–52.
64. Prosser LA, Hammitt JK, Keren R. Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children. Pharmacoeconomics. 2007;25(9):713–26.
65. Cunningham CE, Vaillancourt T, Cunningham LJ, Chen Y, Ratcliffe J. Modeling the bullying prevention program design recommendations of students from grades five to eight: a discrete choice conjoint experiment. Aggress Behav. 2011;37(6):521–37. doi:10.1002/ab.20408.
66. Lloyd A, Dewilde S, Yuen C, Price M, Annemans L, Coghill D. The perceived benefits of dosing schedules for children with ADHD [poster]. In: 7th Annual European Congress of ISPOR, Oct 24–26. Germany: Hamburg; 2004.